1. Home
  2. PARK vs ANIX Comparison

PARK vs ANIX Comparison

Compare PARK & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PARK

Park Dental Partners Inc.

N/A

Current Price

$18.12

Market Cap

81.9M

Sector

Health Care

ML Signal

N/A

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

N/A

Current Price

$2.63

Market Cap

88.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PARK
ANIX
Founded
1972
1982
Country
United States
United States
Employees
1212
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.9M
88.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
PARK
ANIX
Price
$18.12
$2.63
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
21.8K
106.4K
Earning Date
05-13-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
$7.06
N/A
Revenue Next Year
$6.17
N/A
P/E Ratio
$6.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.29
$2.32
52 Week High
$22.62
$5.46

Technical Indicators

Market Signals
Indicator
PARK
ANIX
Relative Strength Index (RSI) 44.20 45.90
Support Level $17.33 $2.44
Resistance Level $19.14 $3.12
Average True Range (ATR) 1.41 0.15
MACD -0.19 -0.00
Stochastic Oscillator 10.45 52.16

Price Performance

Historical Comparison
PARK
ANIX

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: